2 pharmaceutical shares that could make you a fortune

Bilaal Mohamed uncovers two pharmaceutical firms with the potential to deliver substantial shareholder returns.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

International specialist healthcare firm BTG (LSE: BTG) last week lifted its guidance for full-year revenues on the back of a weakened sterling, with FY2017 figures ahead of its previously announced range of £510m to £540m. Although half-year results aren’t formally announced until next month, the firm said that on a constant currency basis, it delivered double-digit revenue growth over the six month period, with the acquisition of US-based Galil Medical in June providing further strength and diversification to its interventional oncology portfolio.

Growth at a reasonable price

The FTSE 250-listed pharmaceuticals firm has a growing portfolio of Interventional Medicine products designed to advance the treatment of cancer tumours, advanced emphysema, severe blood clots, and varicose veins. In addition BTG’s Specialty Pharmaceuticals business offers antidotes that alleviate toxicity and treat rare conditions including snake venoms and the toxicity associated with some heart and cancer medications.

BTG has an excellent track record of growth stretching back over a decade with further earnings expansion forecast for the medium term at least. Analysts are predicting a £99m improvement in revenue to £547m for the full year to 31 March, with pre-tax profits jumping to £89.7m from the £57.5m reported for the last financial year. The forward price-to-earnings ratio of 31 may look expensive for value-focused investors, but this drops to a more palatable 22 for FY2018, well below historical levels and good value for this high growth pharmaceuticals play.

Cost synergies

Meanwhile fellow mid-cap pharmaceuticals group Vectura (LSE: VEC) has raised its expectations for 2016 following its merger with rival SkyePharma, with integration of the two businesses progressing well according to management. The merger was completed in June following approval by the UK’s Competition & Markets Authority with the enlarged £1bn group expecting to achieve cost synergies of around £10m per year from 2018 onwards.

Prior to the merger, Vectura had reported an encouraging set of results for its most recently ended financial year, with revenues up 24% to £72m driven by a 56% leap in royalties to £39.2m. Most encouraging was the news that royalties from recently launched inhaled products were up by a staggering 104% to £25.5m. Pre-tax losses narrowed to £1.9m, compared to £6.2m a year earlier, with underlying earnings per share up by 42%.

The business, which focuses on inhaled airways diseases, is tipped to more-than-double revenues in the current financial year, which incidentally has been shortened to nine months following the company’s decision to move its year-end date from 31 March to 31 December after the merger. Perhaps more significantly, the City expects Vectura to move into the black, with last year’s losses swinging to pre-tax profits forecast at £8m. The future looks good, and I believe Vectura could be an astute buy ahead of interim results on 23 November.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »

Investing Articles

£13,200 invested in this defensive stock bags me £1K of passive income!

Building a passive income stream is possible and this Fool breaks down one investment in a single stock that could…

Read more »

Investing Articles

I think the Rolls-Royce dividend is coming back – but when?

The Rolls-Royce dividend disappeared in 2020 and has not come back. But with the company performance improving, might it reappear?

Read more »

British Pennies on a Pound Note
Investing Articles

Should I snap up this penny share in March?

Our writer is considering penny shares to buy for his portfolio next month. Does this mining company merit a place…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Stock market bubble – or start of a bull run?

Christopher Ruane considers whether the surging NVIDIA share price could be symptomatic of a wider stock market bubble forming.

Read more »

Investing Articles

Buying 8,254 Aviva shares in an empty ISA would give me a £1,370 income in year one

Harvey Jones is tempted to add Aviva shares to his Stocks and Shares ISA this year. Today’s 7.37% yield isn't…

Read more »

Investing Articles

Is the tide turning for bank shares?

Bank shares are trading on stubbornly cheap-looking valuations yet business performance in the sector is broadly robust. Should our writer…

Read more »